Cystic fibrosis (CF) is one of the most common genetic disorders that develops from
a mutation of the cystic fibrosis transmembrane regulator gene. Patients with CF are
known to be at risk for malignancies, and lung transplantation-associated immunosuppression
further increases this risk.We describe a case of a 29-year-old male patient with
CF who developed testicular cancer 14 months after a lung transplantation. Immunosuppressive
therapy included antithymocyte globulin induction and tacrolimus, mycophenolate, and
prednisolone maintenance therapy as compared to standard alemtuzumab induction, followed
by tacrolimus and prednisolone, as used in our center. He underwent semicastration
and refused chemotherapy. Immunosuppressive treatment was changed to tacrolimus, everolimus,
and prednisolone, which did not influence excellent graft function. This case report
highlights the importance of uro-oncological observation of patients with CF following
lung transplantations.
